- authorisedTherapeutic use (Phase IV)
A multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority trial to investigate shortening treatment duration in uncomplicated candidemia: the CanTEN trial
This study, CanTEN, is looking at how long we need to treat a serious fungal infection called candidemia. It compares standard treatment with a shorter course, using common medicines like caspofungin, to see if shorter treatment is just as good and safe for patients.
Germany - recruitingPHASE3
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
This study is testing a new medicine, Fosmanogepix, for serious fungal infections called candidemia or invasive candidiasis. It compares the new medicine to standard treatments to see if it's safe and works just as well. We're looking for adults diagnosed with these infections.
United States · Argentina · Australia - ongoing, recruitingTherapeutic exploratory (Phase II)
Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia
This study is checking a new treatment called Immukine alongside usual care for a serious fungal infection in the blood called candidemia. Researchers want to see if it makes people get better faster and how safe it is.
Netherlands · Greece · Romania